No specific problems have been reported in elderly people forcing a dosing readjustment.
- Warn your doctor and/or pharmacist if symptoms continue or worsen after 2 weeks.
- Tell your doctor and/or pharmacist if you experience any of these symptoms:
* Fever, pain or stinging when urinating or blood appearing in the urine.
- Hypersensitivity to any component of the medicine.
Cases of cross hypersensitivity have been reported between different species of the compound family, so people allergic to other plants in this family (artichoke, marigold, chamomile) should avoid using milk thistle.
- Liver or bile diseases, such as [HEPATITIS], [COLANGITIS] or [COLELITIASIS].
- Active peptic ulcer.
- [INTESTINAL OBSTRUCTION] or hepatic.
It does not appear to have significant effects.
Animal safety: no data available.
Human safety :adequate and well-controlled human studies are not available. It is not recommended for use during pregnancy.
Effects on fertility :no specific human studies have been conducted.
- Symptomatic treatment of [DISPEPSIA], such as indigestion, [GASTRIC HYPERACIDEZ], [ABDOMINAL DISTENSION], [FLATULENCE] and [NAUSEAS].
Its use is based exclusively on a traditional use.
They haven't been described.
Animal safety: no data available.
Human safety :adequate and well-controlled human studies are not available. It is not recommended for use during lactation.
Safety and efficacy in children and adolescents < 18 years have not been evaluated, so it is recommended to avoid its use.
Swallow the tablets with enough fluid.
Food administration :can be taken with or without food.
- Adults: 1 tablet, 2 times a day.
- Children and adolescents < 18 years: not recommended.
- Elderly: no specific dosage recommendations have been made.
Forgetting doses: administer the next dose at the usual time. Do not double the next dose.
No specific dosing recommendations have been made.
No specific dosing recommendations have been made.
- Patients with [RENAL INSUFFICIENCY], [HEPATIC INSUFFICIENCY], [DIABETES] or history of [PEPTICA ULCERA]. Possible aggravation.
Adverse reactions are described according to each frequency interval, considered very common (>10%), common (1-10%), uncommon (0.1-1%), rare (0.01-0.1%), very rare (<0.01%) or of unknown frequency (cannot be estimated from the available data).
- Immune system disorders: unknown frequency [HYPERSENSITIVITY REACTIONS], with [URTICARIA], [EXANTEMATIC ERUPTIONS], [PRURITO].
- Nervous system disorders: unknown frequency [CEFALEA].
- Gastrointestinal disorders: unknown frequency [NAUSEAS], gastric discomfort, [DIARREA], squirming, [ABDOMINAL PAIN], [GASTRIC HYPERACIDEZ].
Symptoms: no cases have been reported.
Measures to be taken:
- Antidote: there is no specific antidote.
- General elimination measures: have not been established.
- Monitoring: clinical condition of the patient.
- Treatment: symptomatic.